FDA Approves Perrigo’s Version of Clarinex

Perrigo Co. Dec. 27, 2011, announced that it has received final approval from the Food and Drug Administration for its generic version of Schering-Plough’s Clarinex (desloratadine) 5 mg tablets.

Clarinex is indicated for the treatment of seasonal allergic rhinitis and perennial allergic rhinitis, the Allegan, Mich.-based company said.

Perrigo had been sued for patent infringement because it filed an abbreviated new drug application for the product and settled the case in 2008 (6 PLIR 1382, 12/12/08). Under the terms of the settlement, Perrigo can commercially launch its generic desloratadine product on July 1, 2012, or earlier in certain ...